Dr. Reddy’s Laboratories has introduced its Difluprednate Ophthalmic Emulsion 0.05%, a therapeutic generic equivalent to Novartis AG’s Durezol (Difluprednate Ophthalmic Emulsion 0.05%) in the U.S. market.
A topical corticosteroid, the product is indicated for treatment of inflammation and pain associated with ocular surgery; and endogenous anterior uveitis. The Durezol brand and generic had U.S. sales of approximately $40 million MAT for the most recent 12 months ending in Nov 2022, the company said citing IQVIA.
Dr. Reddy’s said its Difluprednate Ophthalmic Emulsion 0.05% is available in 5 ml bottles in case packs of 24.
This is a Premium article available exclusively to our subscribers. To read 250+ such premium articles every
month
You have exhausted your free article limit.
Please support quality journalism.
You have exhausted your free article limit.
Please support quality journalism.
The Hindu operates by its editorial values to provide you quality journalism.
You have read {{data.cm.views}} out of {{data.cm.maxViews}} free articles.
This is your last free article.